Evidence map›Paper›PMID 36219353›Full record

ArticleMolecular and cellular biochemistry2023

Constructed the ceRNA network and predicted a FEZF1-AS1/miR-92b-3p/ZIC5 axis in colon cancer.

Xiaoping Yang, Pingfan Wu, Zirui Wang, Xiaolu Su, Zhiping Wu, Xueni Ma, Fanqi Wu, Dekui Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaoping Yang *Key Laboratory of Digestive Diseases of Gansu Province, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Pingfan Wu *Department of Pathology, The 940th Hospital of the Joint Logistic Support of the People's Liberation Army, Lanzhou, 730050, China.
Zirui WangThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Xiaolu SuDepartment of Pathology, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Zhiping WuDepartment of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Xueni MaKey Laboratory of Digestive Diseases of Gansu Province, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Fanqi WuKey Laboratory of Digestive Diseases of Gansu Province, Lanzhou University Second Hospital, Lanzhou, 730030, China.
Dekui ZhangKey Laboratory of Digestive Diseases of Gansu Province, Lanzhou University Second Hospital, Lanzhou, 730030, China. zhangdk8616@126.com.ORCID http://orcid.org/0000-0002-1392-7927
Lanzhou University Second Hospital · CN117th Hospital of People's Liberation Army · CN

Funding

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2021-QN-A05Cuiying Scientific and Technological Key Cultivation Program of Lanzhou University Second Hospital CY2018-ZD01Industrial support and guidance project for institutions of higher learning in Gansu province 2019C-21Lanzhou Science and technology project 2022-ZD-104National Natural Science Foundation of China 81770525Science and technology project of Gansu Province 21JR1RA148
6 · The paper itself

Abstract

The purpose of this study was to identify the role of FEZF1-AS1 in colon cancer and predicted the underlying mechanism. We extracted sequencing data of colon cancer patients from The Cancer Genome Atlas database, identified the differential expression of long noncoding RNA, microRNA, and messenger RNA, constructed a competitive endogenous RNA network, and then analyzed prognosis. Then, we used the enrichment analysis databases for functional analysis. Finally, we studied the FEZF1-AS1/miR-92b-3p/ZIC5 axis. We detected the expression of FEZF1-AS1, miR-92b-3p, and ZIC5 via quantitative reverse transcription-PCR, transfected colon cancer cell RKO with lentivirus and conducted FEZF1-AS1 knockdown, and performed cancer-related functional assays. It indicated that many RNA in the competitive endogenous RNA network, such as ZIC5, were predicted to be related to overall survival of colon cancer patients, and enrichment analysis showed cancer-related signaling pathways, such as PI3K/AKT signaling pathway. The expression of FEZF1-AS1 and ZIC5 was significantly higher and that of miR-92b-3p was lower in the colon cancer than in the normal colon tissues. FEZF1-AS1 promoted the migration, proliferation, as well as invasion of RKO. According to the prediction, FEZF1-AS1 and ZIC5 might competitively bind to miR-92b-3p, leading to the weakening of the inhibitory impact of miR-92b-3p on ZIC5 and increasing expression of ZIC5, thus further activating the PI3K/AKT signaling pathway, which led to the occurrence and development of colon cancer. The study suggested that FEZF1-AS1 might be an effective diagnosis biomarker for colon cancer.

Indexed as

Colonic NeoplasmsMicroRNAsRNA, Long NoncodingCell Line, TumorCell MovementCell ProliferationDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTranscription FactorsDNA-Binding ProteinsMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingTranscription FactorsZIC5 protein, humanBiomarkerColon cancerCompeting endogenous RNA networkFEZF1-AS1lncRNASurvival

Identifiers

PMID36219353
OpenAlexW4304185380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.